To predict, diagnose and monitor acute circulatory failure

sphingotest® bio-ADM is the only immunoassay to measure the plasma level of biological active Adrenomedullin (ADM), in contrast to methods that detect inactive precursor fragments of ADM, that are not suitable for timely monitoring.

Adrenomedullin is a vasodilatory hormone that regulates blood pressure and plays an essential role in the development of acute circulatory failure. bio-ADM is a valuable biomarker for the prediction, diagnosis and monitoring of acute circulatory failure, e.g. septic shock.

Simple validated cut-off

High risk of shock

bio-ADM concentration
70 pg/mL

Low risk of shock
To support early intervention in acute circulatory failure

bio-ADM identifies patients that are likely to develop a circulatory failure in the near future – supporting timely management of patients with high risk of shock, e.g. in sepsis.

Recent studies show a compelling relationship between the time to initiate vasopressor therapy and shock survival: The earlier the patient recieves vasopressors, the higher is the survival rate.

Prediction and diagnosis

![Graph showing the relationship between bio-ADM concentration, blood pressure, and shock]

- **blood pressure ↓**
- **bio-ADM ↑**
- **70 pg/mL**
- **1 - 2 days**
To improve shock management and hospital outcome

Serial bio-ADM measurement enables close monitoring of the change in risk of acute circulatory failure and monitoring of shock treatment.

bio-ADM level show if a patient is responding to the treatment, thereby supporting patient management and discharge decision.

Monitoring
sphingotest® bio-ADM: A dynamic marker for vascular integrity

**Reliable**

- Worldwide validated in ten-thousands of patients
- Simple and robust cut-off
- Independent of comorbidities and inflammation

**Practical**

- Blood e.g. plasma as sample matrix
- Stable at room temperature
- 1 hour to result

**Valuable**

- Prediction of acute circulatory failure enables earlier treatment, e.g. vasopressor therapy
- Close monitoring supports patient management and discharge decision
sphingotest®
acute biomarkers

Early prediction for early intervention
Close monitoring for discharge decision
Unaffected by comorbidities and inflammation
Simple and robust cut-off
Easy handling of blood samples

sphingotest® bio-ADM
Prediction, Diagnosis and Monitoring of Acute Circulatory Failure e.g. in Sepsis and Incomplete Decongestion in Acute Heart Failure

sphingotest® penKid
Prediction, Diagnosis and Monitoring of Acute Kidney Injury

For further information please contact:
+49 3302 20565-0 | info@sphingotec.de
sphingotec GmbH
Neuendorfstrasse 15A | 16761 Hennigsdorf | Germany | www.sphingotec.com